. 2020 Jul 30;9(8):824–833. doi: 10.1530/EC-20-0176
This work is licensed under a Table 1.
General characteristics of the included patients.
| Variables | Value/number |
|---|---|
| Age (years) | 59.1 ± 16.0 |
| Sex (M/F) | 13/16 |
| Time from diagnosis (years) | 13.3 ± 12.9 |
| Initial MRI: micro/macro-adenoma (n = 26) | 5/21 |
| IGF-1 at diagnosis (UNL, n = 15) | 2.89 ± 1.57 |
| Patients status | |
| Controlled, n | 15 |
| Cured, n | 7 |
| Normalized without treatment, n | 4 |
| Normalized with current treatment, n | 4 |
| Uncontrolled , n | 14 |
| Current GH (ng/mL, n = 27) | 2.07 ± 2.50 |
| Current IGF-1 all patients (UNL, n = 29) | 1.02 ± 0.59 |
| IGF-1 controlled (UNL, n = 15) | 0.57 ± 0.26 |
| IGF-1 uncontrolled (UNL, n = 14) | 1.50 ± 0.44 |
| Previous treatment | |
| Pituitary surgery, n | 22 |
| Pituitary radiotherapy, n | 5 |
| Medical treatment, n | 20 |
| Dopamine agonist, n | 7 |
| Somatostatin receptor ligands, n | 20 |
| GH receptor antagonist, n | 4 |
| Never treated, n | 3 |
| Complications | |
| Number of complications per patient | 3.7 ± 1.7 |
| Diabetes, n | 9 |
| Hypertension, n | 13 |
| Dyslipidemia, n | 14 |
| Cardiovascular complications, n | 12 |
| Joints complications, n | 20 |
| Gut complications, n | 21 |
| Thyroid complications, n | 18 |
| Pituitary failure, n (at least one axis) | 12 |
| AcroQoL total score (%, n = 24) | 69.2 ± 16.5 |
| Physical dimension (%, n = 24) | 70.3 ± 19.6 |
| Appearance dimension (%, n = 24) | 58.3 ± 21.3 |
| Personal relation dimension (%, n = 24) | 78.7 ± 16.4 |
| EPICES score (n = 25) | 13.3 ± 15.4 |
Number of assessed patients: n = 29 except otherwise mentioned. Data are given as absolute numbers or mean ± s.d. IGF-1 results are expressed as the fold increase of the upper normal limit (UNL) of the test for each patient.
F, female; M, male.